4组短程三联方案根除幽门螺杆菌的药物经济学评价  

Pharmacoeconomic Evaluation of Four Short-term Triple Therapeutic Schemes for Eradicating Hp

作　　者：程华丰[1] 曹惠明[1] 陈倩[1] 张楠森[1] 

机构地区：[1]上海第二医科大学附属仁济医院药剂科,上海市200001

出　　处：《中国药房》2001年第3期154-155,共2页China Pharmacy

摘　　要：目的 :为有限的医药费用提供一种合理的配置。方法 :根据文献选择了幽门螺杆菌 (Hp)阳性感染的十二指肠溃疡和胃炎患者892例 ,随机分为4组 ,给予不同的短程三联治疗方案 :OMC组 (奥美拉唑 +甲硝唑 +克拉霉素 )、OFC组 (奥美拉唑 +呋喃唑酮 +克拉霉素 )、OFA组 (奥美拉唑 +呋喃唑酮 +羟氨苄青霉素 )、BFC组 (胶体次枸橼酸铋 +呋喃唑酮 +克拉霉素 ) ,运用药物经济学的成本 -效果分析方法进行评价。结果 :OMC、OFC、OFA、BFC4组方案对胃炎/十二指肠溃疡的成本 -效果比为16 19/17 33、17 30/13 93、11 40/10 56、11 17/10 75。经敏感度分析后为16 36/17 51、17 49/14 08、8 15/7 55、11 66/11 22。结论 :OFA组方案为根除HpOBJECTIVE:Four different one-week triple therapeutic schemes to eradicate Helicobacter pylori were compared by pharmacoeconomic analysis to provide a scientific method for rational assignment of our limited medical fund.METHODS:According to literature reports,892 cases of duodenal ulcer and gastritis with Helicobacter pylori were selected.These patients were randomly divided into four groups which received different one-week triple therapeutic schemes:OMC(Omeprazole+Metronidazole+Clarithromycin),OFC(Omeprazole+Furazolidone+Clarithromycin),OFA(Omeprazole+Furazolidone+Amoxicillin)and BFC(Colloidal bismuth subcitrate+Furazolidone+Clarithromycin).The schemes were evaluated with pharmacoeconomic cost-effectiveness analysis.RESULTS:The cost-effectiveness ratios of OMC,OFC,OFA,BFC for gastritis or duodenal ulcer were 16.19/17.33,17.30/13.93,11.40/10.56,11.17/10.75 respectively.They changed to 16.36/17.51,17.49/14.08,8.15/7.55,11.66/11.20 by sensitivity analysis.CONCLUSION:OFA is the most effective and inexpensive one to era_dicate Hp.

关 键 词：幽门螺杆菌 药物经济学 三联疗法 成本-效果分析 

分 类 号：F407.75[经济管理—产业经济]